Abstract
Introduction: Heparin-induced thrombocytopenia (HIT) is a serious complication associated with heparin therapy, characterized by an immune reaction involving antibodies against heparin-platelet factor 4 (PF4). This immune complex formation triggers platelet activation, blood clotting, and reduced platelet counts. Several factors, including previous heparin exposure, duration of exposure, and certain comorbidities, have been examined as potential risk factors for HIT development. In this study, our objective was to determine the incidence of HIT and identify predictive factors associated with its occurrence. Methods: We conducted an analysis using the National Inpatient Sample (NIS) data from 2020 to investigate the incidence of HIT during that year and its correlation with specific comorbidities. Patient identification was based on the International Classification of Diseases (ICD-10) code D75.82. The incidence and associated comorbidities were evaluated using multivariate logistic analysis with Stata 17. Results: Among the 32,355,827 adult patients admitted throughout the United States in 2020, a total of 11,380 cases of HIT were identified. The incidence of HIT was significantly higher in male patients, obese individuals, those with acute kidney injury (AKI), chronic kidney disease (CKD), type II diabetes mellitus (DMII), heart failure (HF), primary hypercoagulable states, and autoimmune diseases such as systemic lupus erythematosus (SLE). The highest risk of developing HIT was observed in patients with thrombophilia (OR 4.17, 95% CI 3.66-4.75, P = .000), AKI (OR 3.53, 95% CI 3.19-3.91, P = .000), and HF (OR 2.10, 95% CI 1.90-2.33, P = .000). Among autoimmune diseases studied, only SLE was associated with an increased odds ratio for developing HIT (OR 1.60, 95% CI 1.06-2.41, P = .026). Conclusion: The incidence of HIT varies and is influenced by the presence of specific comorbidities. Further studies are recommended to investigate additional factors that may increase the likelihood of HIT development. This information could aid in validating and implementing standard precautionary measures in patients at higher risk of developing HIT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.